Skip to Content
Merck
All Photos(1)

Key Documents

A4810

Sigma-Aldrich

3′-Azido-2′,3′-dideoxyuridine

≥98% (TLC)

Sign Into View Organizational & Contract Pricing


About This Item

Empirical Formula (Hill Notation):
C9H11N5O4
CAS Number:
Molecular Weight:
253.21
MDL number:
UNSPSC Code:
12352200
PubChem Substance ID:

Assay

≥98% (TLC)

storage temp.

−20°C

SMILES string

OC[C@H]1O[C@H](C[C@H]1N=[N+]=[N-])N2C=CC(=O)NC2=O

Application

3′-Azido-2′,3′-dideoxyuridine has shown potent anti-HIV activity in vitro.

Biochem/physiol Actions

Inhibitor of HIV replication.

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Personal Protective Equipment

dust mask type N95 (US), Eyeshields, Gloves

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

B F Eriksson et al.
Antimicrobial agents and chemotherapy, 33(10), 1729-1734 (1989-10-01)
3'-Azido-2',3'-dideoxyuridine-5'-triphosphate was found to be a potent and highly selective inhibitor of human immunodeficiency virus type 1 and simian immunodeficiency virus reverse transcriptases. The affinity of 3'-azido-2',3'-dideoxyuridine-5'-triphosphate for the reverse transcriptases was similar to that observed for 3'-azido-3'-deoxythymidine-5'-triphosphate. Both compounds
Linghui Kong et al.
Antiviral chemistry & chemotherapy, 14(5), 263-270 (2003-12-26)
3'-Azido-2', 3'-dideoxyuridine (AZDU, AzddU, CS-87) has been shown to have potent anti-HIV activity in vitro. However, the compound exhibits a relatively short half-life and incomplete oral bioavailability in humans. In an effort to improve the pharmacokinetic properties of AZDU, prodrug
C K Chu et al.
Journal of medicinal chemistry, 33(8), 2188-2192 (1990-08-01)
A significant number of patients with AIDS and AIDS-related complex develop neurological complications. Therefore, it is critical that anti-HIV agents penetrate the blood-brain barrier and suppress viral replication in the brain. In an effort to increase the brain delivery of
Pharmacokinetic evaluation of 3'-azido-2', 3'-dideoxyuridine-5'-O-valinate-hydrochloride as a prodrug of the anti-HIV nucleoside 3'-azido-2', 3'-dideoxyuridine
Kong, L., et al.
Antiviral Chem. Chemother., 14, 263-270 (2003)
K J Doshi et al.
Drug metabolism and disposition: the biological fate of chemicals, 17(6), 590-594 (1989-11-01)
The pharmacokinetics of 3'-azido-3'-deoxythymidine (AZT) and 3'-azido-2',3'-dideoxyuridine (AZddU, CS-87), active anti-HIV compounds, were characterized in uninfected mice. Sensitive and specific HPLC techniques were used to quantitate AZT and AZddU concentrations in serum and brain homogenates following iv doses of 50

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service